

References

1. Collins PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In: Knipe DM, Howley PM, editors. *Fields Virology*. Philadelphia, Lippincott Williams & Wilkins, 2001: 1443-85.
2. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K. 1985. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. *J Infect Dis* **151**:626-33.
3. Mufson MA, Belshe RB, Orvell C, Norrby E. 1988 Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. *J Infect Dis* **157**:143-8.
4. Mufson MA, Orvell C, Rafnar B, Norrby E. 1985. Two distinct subtypes of human respiratory syncytial virus. *J Gen Virol* **66**:2111-24.
5. Kahn JS, Schnell MJ, Buonocore L, Rose JK. 1999. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. *Virology* **254**:81-91.
6. Wertz GW, Krieger M, Ball LA. 1989. Structure and cell surface maturation of the attachment glycoprotein of human respiratory syncytial virus in a cell line deficient in O glycosylation. *J Virol* **63**:4767-76.
7. Feldman SA, Hendry RM, Beeler JA. 1999. Identification of a linear heparin binding domain for human respiratory syncytial virus attachment glycoprotein G. *J Virol* **73**:6610-7.
8. Teng MN, Whitehead SS, Collins PL. 2001. Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. *Virology* **289**:283-96.
9. Langedijk JPM, Schaaper WMM, Meloen RH, Van Oirschot JT. 1996. Proposed three-dimensional model for the attachment protein G of respiratory syncytial virus. *J Gen Virol* **77**:1249-57.
10. Heminway BR, Yu Y, Galinski MS. 1994. Paramyxovirus mediated cell fusion requires co-expression of both the fusion and hemagglutinin-neuraminidase glycoproteins. *Virus Res* **31**:1-16.
11. Techaarpomkul S, Barretto N, Peeples ME. 2001. Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene. *J Virol* **75**:6825-34.
12. Grosfeld H, Hill MG, Collins PL. 1995. RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA. *J Virol* **69**:5677-86.
13. Fearn R, Collins PL. 1999. Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. *J Virol* **73**:5852-64.
14. Teng MN, Collins PL. 1999. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. *J Virol* **73**:466-73.
15. Teng MN, Whitehead SS, Bermingham A, St.Claire M, Elkins WR, Murphy BR, Collins PL. 2000. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. *J Virol* **74**:9317-21.

16. Bermingham A, Collins PL. 1999. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. *Proc Natl Acad Sci USA* **96**:11259-64.
17. Simoes EAF. 1999. Respiratory syncytial virus infection. *Lancet* **354**:847-52.
18. Carbonell-Estrany X, Quero J. 2001. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. *Pediatr Infect Dis J* **20**:874-9.
19. MacDonald NE, Hall CB, Suffin SC, Alexson C, Harris PJ, Manning JA. 1982. Respiratory syncytial viral infection in infants with congenital heart disease. *N Engl J Med* **307**:397-400.
20. Groothuis JR, Gutierrez KM, Lauer BA. 1988. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. *Pediatrics* **82**:199-203.
21. Hall CB, Geiman JM, Biggar R, Kotok DI, Hogan PM, Douglas GR, Jr. 1976. Respiratory syncytial virus infections within families. *N Engl J Med* **294**:414-9.
22. Hall WJ, Hall CB, Speers DM. 1978. Respiratory syncytial virus infection in adults: clinical, virologic, and serial pulmonary function studies. *Ann Intern Med* **88**:203-5.
23. Falsey AR, Walsh EE. 2000. Respiratory syncytial virus infection in adults. *Clin Microbiol Rev* **13**:371-84.
24. Han LL, Alexander JP, Anderson LJ. 1999. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. *J Infect Dis* **179**:25-30.
25. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB. 1989. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. *Medicine (Baltimore)* **68**:269-81.
26. Whimbey E, Couch RB, Englund JA, Andreeff M, Goodrich JM, Raad II, Lewis V, Mirza N, Luna MA, Baxter B. 1995. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. *Clin Infect Dis* **21**:376-9.
27. Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, Benson A, Meyers JD. 1992. An outbreak of respiratory syncytial virus in a bone marrow transplant center. *J Infect Dis* **165**:987-93.
28. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. 1986. Respiratory syncytial viral infection in children with compromised immune function. *N Engl J Med* **315**:77-81.
29. Chandwani S, Borkowsky W, Krasinski K, Lawrence R, Welliver R. 1990. Respiratory syncytial virus infection in human immunodeficiency virus-infected children. *J Pediatr* **117**:251-4.
30. Garofalo R, Weliver RC, Ogra PL. Clinical aspects of bronchial reactivity and cell-virus interaction. In: Ogra PL, Lamm ME, Bienenstock J, Mestecky J, Strober W, McGhee JR, editors. *Mucosal Immunology*. San Diego, Academic Press, **1999**: 1223-37.
31. Jafri HS. 2002. Role of chemokines in respiratory syncytial virus disease. *Pediatr Infect Dis J* **21**:454-6.
32. Zach TL, Hill LD, Herrman VA, Leuschen MP, Hostetter MK. 1992. Effect of glucocorticoids on C3 gene expression by the A549 human pulmonary epithelial cell line. *J Immunol* **148**:3964-9.
33. Korfhagen TR, Whitsett JA. 1997. Transcriptional control in the developing lung. The Parker B. Francis lectureship. *Chest* **111**:83S-8S.
34. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. *J Infect Dis* **163**:693-8.

35. Becker S, Soukup JM. 1999. Airway epithelial cell-induced activation of monocytes and eosinophils in respiratory syncytial viral infection. *Immunobiol* **201**:88-106.
36. Wang SZ, Forsyth KD. 2000. The interaction of neutrophils with respiratory epithelial cells in viral infection. *Respirology* **5**:1-10.
37. Everard ML, Swarbrick A, Wraitham M, McIntyre J, Dunkley C, James PD, Sewell HF, Milner AD. 1994. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. *Arch Dis Child* **71**:428-32.
38. Faden H, Hong JJ, Ogra PL. 1984. Interaction of polymorphonuclear leukocytes and viruses in humans: adherence of polymorphonuclear leukocytes to respiratory syncytial virus-infected cells. *J Virol* **52**:16-23.
39. Stark JM, Godding V, Sedgwick JB, Busse WW. 1996. Respiratory syncytial virus infection enhances neutrophil and eosinophil adhesion to cultured respiratory epithelial cells. *J Immunol* **156**:4774-82.
40. Garofalo RP, Haeberle H. 2000. Epithelial regulation of innate immunity to respiratory syncytial virus. *Am J Respir Cell Mol Biol* **23**:581-5.
41. Olszewska-Pazdrak B, Pazdrak K, Ogra PL, Garofalo RP. 1998. Respiratory syncytial virus-infected pulmonary epithelial cells induce eosinophil degranulation by a CD18-mediated mechanism. *J Immunol* **160**:4889-95.
42. Domachowske JB, Rosenberg HF. 1999. Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment. *Clin Microbiol Rev* **12**:298-309.
43. Shastri N, Serwold T, Paz P. 1998. Reading within the lines: naturally processed peptides displayed by MHC class I molecules. *Curr Opin Immunol* **10**:137-44.
44. Yewdell J, Anton LC, Bacik I, Schubert U, Snyder HL, Bennink JR. 1999. Generating MHC class I ligands from viral gene products. *Immunol Rev* **172**:97-108.
45. Niedermann G, Geier E, Lucchiari-Hartz M, Hitziger N, Ramsperger A, Eichmann K. 1999. The specificity of proteasomes: impact on MHC class I processing and presentation of antigens. *Immunol Rev* **172**:29-48.
46. Pieters J. 2000. MHC class II-restricted antigen processing and presentation. *Adv Immunol* **75**:159-208.
47. Williams TM. 2001. Human leukocyte antigen gene polymorphism and the histocompatibility laboratory. *J Mol Diagn* **3**:98-104.
48. Parrott RH, Kim HW, Arrobio JO, Hodes DS, Murphy BR, Brandt CD, Camargo E, Chanock RM. 1973. Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. *Am J Epidemiol* **98**:289-300.
49. Moylett EH, Piedra PA. 1999. Respiratory syncytial virus infection: diagnosis, treatment, and prevention. *Hosp Med* **35**:10-7.
50. Harsten G, Prellner K, Lofgren B, Heldrup J, Kalm O, Kornfalt R. 1989. Serum antibodies against respiratory tract viruses: a prospective three-year follow-up from birth. *J Laryngol Otol* **103**:904-8.
51. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. 1978. The immunologic response to infection with respiratory syncytial virus in infants. *J Infect Dis* **138**:24-32.
52. Brandenburg AH, Groen J, Van Steensel-Moll HA, Claas EJC, Rothbarth PH, Neijens HJ, Osterhaus ADME. 1997. Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection. *J Med Virol* **52**:97-104.
53. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, Rodriguez WJ, Chanock RM. 1986. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. *J Clin Microbiol* **24**:197-202.

54. Taylor G, Stott EJ, Hughes M, Collins AP. 1984. Respiratory syncytial virus infection in mice. *Infect Immun* **43**:649-55.
55. Prince GA, Horswood RL, Chanock RM. 1985. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. *J Virol* **55**:517-20.
56. Simoes EA, Groothuis JR. 2002. Respiratory syncytial virus prophylaxis--the story so far. *Respir Med* **96**:S15-S24.
57. Devincenzo JP, Aitken J, Harrison L. 2003. Respiratory syncytial virus (RSV) loads in premature infants with and without prophylactic RSV fusion protein monoclonal antibody. *J Pediatr* **143**:123-6.
58. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. 2003. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. *Vaccine* **21**:3479-82.
59. Good RA, Zak SJ. 1956. Disturbances in gamma globulin synthesis as "experiments of nature". *Pediatrics* **18**:109-49.
60. Delage G, Brochu P, Robillard L, Jasmin G, Joncas JH, Lapointe N. 1984. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. *Arch Pathol Lab Med* **108**:623-5.
61. Fishaut M, Tubergen D, McIntosh K. 1980. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. *J Pediatr* **96**:179-86.
62. Cannon MJ, Stott EJ, Taylor G, Askonas BA. 1987. Clearance of persistent respiratory syncytial virus infections in immunodeficient mice following transfer of primed T cells. *Immunology* **62**:133-8.
63. Bangham CRM, Openshaw PJM, Ball LA, King AM, Wertz GW, Askonas BA. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. *J Immunol* **137**:3973-7.
64. Graham BS, Rutigliano JA, Johnson TR. 2002. Respiratory syncytial virus immunobiology and pathogenesis. *Virology* **297**:1-7.
65. Anderson JJ, Harrop JA, Peers H, Turnbull T, Toms GL, Scott R. 1991. Recognition of respiratory syncytial (RS) virus proteins by human and BALB/c CD4⁺ lymphocytes. *J Med Virol* **35**:165-73.
66. Varga SM, Wissinger EL, Braciale TJ. 2000. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4⁺ T cell responses. *J Immunol* **165**:6487-95.
67. Rock MT, Crowe Jr. JE. 2003. Identification of a novel human leucocyte antigen-A*01-restricted cytotoxic T-lymphocyte epitope in the respiratory syncytial virus fusion protein. *Immunology* **108**:474-80.
68. Goulder PJR, Lechner F, Klennerman P, McIntosh K, Walker BD. 2000. Characterization of a novel respiratory syncytial virus-specific human cytotoxic T-lymphocyte epitope. *J Virol* **74**:7694-7.
69. Venter M, Rock M, Puren AJ, Tiemessen CT, Crowe Jr. JE. 2003. Respiratory syncytial virus nucleoprotein-specific cytotoxic T-cell epitopes in a South African population of diverse HLA types are conserved in circulating field strains. *J Virol* **77**:7319-29.
70. Van Bleek GM, Poelen MC, Van der Most R, Brugghe HF, Timmermans HAM, Boog CJ, Hoogerhout P, Otten HG, Van Els CACM. 2003. Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells. *J Virol* **77**:980-8.

71. Lively ME, Bannow CA, Smith CW, Nicholas JA. 1991. Immunodominant T-cell epitope on the F protein of respiratory syncytial virus recognized by human lymphocytes. *J Virol* **65**:3789-96.
72. Chang J, Srikiatkachorn A, Braciale TJ. 2001. Visualization and characterization of respiratory syncytial virus F-specific CD8⁺ T cells during experimental virus infection. *J Immunol* **167**:4254-60.
73. Jiang S, Borthwick NJ, Morrison P, Gao GF, Steward MW. 2002. Virus-specific CTL responses induced by an H-2Kd-restricted, motif-negative 15-mer peptide from the fusion protein of respiratory syncytial virus. *J Gen Virol* **83**:429-38.
74. Kulkarni AB, Morse III HC, Bennink JR, Yewdell JW, Murphy BR. 1993. Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8⁺ cytotoxic T cells. *J Virol* **67**:4086-92.
75. Boyton RJ, Openshaw PJM. 2002. Pulmonary defences to acute respiratory infection. *Br Med Bull* **61**:1-12.
76. Freihost J, Ogra PL. 2001. Mucosal immunity and viral infections. *Ann Med* **33**:172-7.
77. Pilette C, Ouadrhiri Y, Godding V, Vaerman JP, Sibille Y. 2001. Lung mucosal immunity: immunoglobulin-A revisited. *Eur Respir J* **18**:571-88.
78. Crowe Jr. JE. 1999. Host responses to respiratory syncytial virus infection. *Curr Top Microbiol Immunol* **236**:191-214.
79. Simoes EAF. 2001. Overlap between respiratory syncytial virus infection and influenza. *Lancet* **358**:1382-3.
80. Zambon MC, Stockton JD, Clewley JP, Fleming DM. 2001. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. *Lancet* **358**:1410-6.
81. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. 1988. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. *N Engl J Med* **319**:1112-7.
82. Hall CB, Douglas Jr. RG, Schabel KC, Geiman JM. 1981. Infectivity of respiratory syncytial virus by various routes of inoculation. *Infect Immun* **33**:779-83.
83. Greensill J, McNamara PS, Dove W, Flanagan B, Smyth RL, Hart CA. 2003. Human metapneumovirus in severe respiratory syncytial virus bronchiolitis. *Emerg Infect Dis* **9**:372-5.
84. Everard ML. 1999. What link between early respiratory viral infections and atopic asthma? *Lancet* **354**:527-8.
85. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. *Am J Epidemiol* **89**:422-34.
86. Openshaw PJM, Culley FJ, Olszewska W. 2001. Immunopathogenesis of vaccine-enhanced RSV disease. *Vaccine* **20**:S27-S31.
87. Roman M, Calhoun WJ, Hinton KL, Avendano LF, Simon V, Escobar AM, Gaggero A, Diaz PV. 1997. Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. *Am J Respir Crit Care Med* **156**:190-5.
88. Brandenburg AH, Kleinjan A, van het Land B, Moll HA, Timmerman HH, De Swart RL, Neijens HJ, Fokkens W, Osterhaus ADME. 2000. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. *J Med Virol* **62**:267-77.
89. Kon OM, Kay AB. 1999. T cells and chronic asthma. *Int Arch Allergy Immunol* **118**:133-5.
90. Bendelja K, Gagro A, Bace A, Lokar-Kolbas R, Krsulovic-Hresic V, Drazenovic V, Mlinaric-Galinovic G, Rabatic S. 2000. Predominant type-2 response in infants with

- respiratory syncytial virus (RSV) infection demonstrated by cytokine flow cytometry. *Clin Exp Immunol* **121**:332-8.
91. Pala P, Bjarnason R, Sigurbergsson F, Metcalfe C, Sigurs N, Openshaw PJM. 2002. Enhanced IL-4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy. *Eur Respir J* **20**:376-82.
 92. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. 2003. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. *Am J Respir Crit Care Med* **168**:633-9.
 93. Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, Kundi M, Popow-Kraupp T. 1999. Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. *Am J Respir Crit Care Med* **160**:1263-8.
 94. Aoyagi M, Shimojo N, Sekine K, Nishimuta T, Kohno Y. 2003. Respiratory syncytial virus infection suppresses IFN-gamma production of gammadelta T cells. *Clin Exp Immunol* **131**:312-7.
 95. Welliver RC, Garofalo RP, Ogra PL. 2002. Beta-chemokines, but neither T helper type 1 nor T helper type 2 cytokines, correlate with severity of illness during respiratory syncytial virus infection. *Pediatr Infect Dis J* **21**:457-61.
 96. Tripp RA, Moore D, Barskey A, Jones L, Moscattiello C, Keyserling H, Anderson LJ. 2002. Peripheral blood mononuclear cells from infants hospitalized because of respiratory syncytial virus infection express T helper-1 and T helper-2 cytokines and CC chemokine messenger RNA. *J Infect Dis* **185**:1388-94.
 97. Van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC, Welliver RC. 1999. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. *J Allergy Clin Immunol* **103**:630-6.
 98. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. 2000. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. *Am J Respir Crit Care Med* **161**:1501-7.
 99. Stein RT, Sherrill D, Morgan WJ, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. 1999. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. *Lancet* **354**:541-5.
 100. Forster J, Tacke U, Krebs H, Streckert HJ, Werchau H, Bergmann RL, Schulz J, Lau S, Wahn U. 1996. Respiratory syncytial virus infection: its role in aeroallergen sensitization during the first two years of life. *Pediatr Allergy Immunol* **7**:55-60.
 101. Welliver RC, Sun M, Rinaldo D, Ogra PL. 1986. Predictive value of respiratory syncytial virus-specific IgE responses for recurrent wheezing following bronchiolitis. *J Pediatr* **109**:776-80.
 102. Welliver RC, Duffy L. 1993. The relationship of RSV-specific immunoglobulin E antibody responses in infancy, recurrent wheezing, and pulmonary function at age 7-8 years. *Pediatr Pulmonol* **15**:19-27.
 103. Renzi PM, Turgeon JP, Yang JP, Drblik SP, Marcotte JE, Pedneault L, Spier S. 1997. Cellular immunity is activated and a Th-2 response is associated with early wheezing in infants after bronchiolitis. *J Pediatr* **130**:584-93.
 104. Martinez FD, Stern DA, Wright AL, Taussig LM, Halonen M. 1998. Differential immune responses to acute lower respiratory illness in early life and subsequent development of persistent wheezing and asthma. *J Allergy Clin Immunol* **102**:915-20.
 105. Schwarze J, Gelfand EW. 2000. The role of viruses in development or exacerbation of atopic asthma. *Clin Chest Med* **21**:279-87.
 106. Tuffaha A, Gern JE, Lemanske RFJ. 2000. The role of respiratory viruses in acute and chronic asthma. *Clin Chest Med* **21**:289-300.

107. Peebles Jr. RS, Sheller JR, Johnson JE, Mitchell DB, Graham BS. 1999. Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice. *J Med Virol* **57**:186-92.
108. Matsuse H, Behera AK, Kumar M, Rabb J, Lockey RF, Mohapatra SS. 2000. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. *J Immunol* **164**:6583-92.
109. Peebles Jr. RS, Sheller JR, Collins RD, Jarzecka K, Mitchell DB, Graham BS. 2000. Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. *J Infect Dis* **182**:671-7.
110. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, Donaldson DD. 1998. Interleukin-13: central mediator of allergic asthma. *Science* **282**:2258-61.
111. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, Zhang Y, Elias JA. 1999. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J Clin Invest* **103**:779-88.
112. Lukacs NW, Tekkanat KK, Berlin A, Hogaboam CM, Miller A, Evanoff H, Lincoln P, Maassab H. 2001. Respiratory syncytial virus predisposes mice to augmented allergic airway responses via IL-13-mediated mechanisms. *J Immunol* **167**:1060-5.
113. Tekkanat KK, Maassab HF, Cho DS, Lai JJ, John A, Berlin A, Kaplan MH, Lukacs NW. 2001. IL-13-induced airway hyperactivity during respiratory syncytial virus infection is STAT6 dependent. *J Immunol* **166**:3542-8.
114. Beghe B, Barton S, Rorke S, Peng Q, Sayers I, Gaunt T, Keith TP, Clough JB, Holgate ST, Holloway JW. 2003. Polymorphisms in the interleukin-4 and interleukin-4 receptor alpha chain genes confer susceptibility to asthma and atopy in a Caucasian population. *Clin Exp Allergy* **33**:1111-7.
115. Zurawski SM, Vega F, Jr., Huyghe B, Zurawski G. 1993. Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction. *EMBO J* **12**:2663-70.
116. Wills-Karp M. 1999. Immunologic basis of antigen-induced airway hyperresponsiveness. *Annu Rev Immunol* **17**:255-81.
117. Wohlfahrt JG, Kunzmann S, Menz G, Kneist W, Akdis CA, Blaser K, Schmidt-Weber CB. 2003. T cell phenotype in allergic asthma and atopic dermatitis. *Int Arch Allergy Immunol* **131**:272-82.
118. Crowe Jr. JE. 2001. Respiratory syncytial virus vaccine development. *Vaccine* **20**:S32-S37.
119. Piedra PA. 2003. Clinical experience with respiratory syncytial virus vaccines. *Pediatr Infect Dis J* **22**:S94-S99.
120. Henderson FW, Collier AM, Clyde Jr. WA, Denny FW. 1979. Respiratory syncytial virus infections, reinfections and immunity: a prospective, longitudinal study in young children. *N Engl J Med* **300**:530-4.
121. Crowe Jr. JE. 2001. Influence of maternal antibodies on neonatal immunization against respiratory viruses. *Clin Infect Dis* **33**:1720-7.
122. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. *Am J Epidemiol* **89**:405-21.
123. McCormack GP, Clewley JP. 2002. The application of molecular phylogenetics to the analysis of viral genome diversity and evolution. *Rev Med Virol* **12**:221-38.

124. Anderson LJ, Heilman CA. 1995. Protective and disease-enhancing immune responses to respiratory syncytial virus. *J Infect Dis* **171**:1-7.
125. Openshaw PJM. 1995. Immunity and immunopathology to respiratory syncytial virus. The mouse model. *Am J Respir Crit Care Med* **152**:S59-S62.
126. Srikiatkachorn A, Braciale TJ. 1997. Virus-specific CD8⁺ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. *J Exp Med* **186**:421-32.
127. Walzl G, Tafuro S, Moss P, Openshaw PJM, Hussell T. 2000. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. *J Exp Med* **192**:1317-26.
128. De Swart RL, Kuiken T, Timmerman HH, Van Amerongen G, van den Hoogen BG, Vos HW, Neijens HJ, Andeweg AC, Osterhaus ADME. 2002. Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection. *J Virol* **76**:11561-9.
129. Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, Lirman DD, Rabold R, Hoffman SJ, Karp CL, Kleeberger SR, Wills-Karp M, Karron RA. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. *J Exp Med* **196**:859-65.
130. Collins PL, Murphy BR. 2002. Respiratory syncytial virus: reverse genetics and vaccine strategies. *Virology* **296**:204-11.
131. Olmsted RA, Buller RML, Collins PL, London WT, Beeler JA, Prince GA, Chanock RM, Murphy BR. 1988. Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus. *Vaccine* **6**:519-24.
132. Hsu KH, Lubeck MD, Davis AR, Bhat RA, Selling BH, Bhat BM, Mizutani S, Murphy BR, Collins PL, Chanock RM. 1992. Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee. *J Infect Dis* **166**:769-75.
133. Kahn JS, Roberts A, Weibel C, Buonocore L, Rose JK. 2001. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge. *J Virol* **75**:11079-87.
134. Chen M, Hu KF, Rozell B, Orvell C, Morein B, Liljestrom P. 2002. Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. *J Immunol* **169**:3208-16.
135. Haller AA, Mitiku M, MacPhail M. 2003. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. *J Gen Virol* **84**:2153-62.
136. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. 2003. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. *J Virol* **75**:4594-603.
137. Power UF, Nguyen TN, Rietveld E, De Swart RL, Groen J, Osterhaus ADME, de Groot R, Corvaia N, Beck A, Bouveret-le-Cam N, Bonnefoy JY. 2001. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. *J Infect Dis* **184**:1456-60.
138. Piedra PA, Cron SG, Jewell A, Hamblett N, McBride R, Palacio MA, Ginsberg R, Oermann CM, Hiatt PW. 2003. Immunogenicity of a new purified fusion protein

- vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. *Vaccine* **21**:2448-60.
139. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFV-2) vaccine in seropositive children with bronchopulmonary dysplasia. *J Infect Dis* **177**:467-9.
 140. Tristram DA, Welliver RC, Hogerman DA, Hildreth SW, Paradiso P. 1994. Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFV-1: evaluation of antibody persistence and possible disease enhancement. *Vaccine* **12**:551-6.
 141. Prince GA, Capiou C, Deschamps M, Fabry L, Garcon N, Gheysen D, Prieels J-P, Thiry G, Van Opstal O, Porter DD. 2000. Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats. *J Virol* **74**:10287-92.
 142. Brideau RJ, Wathen MW. 1991. A chimeric glycoprotein of human respiratory syncytial virus termed FG induces T-cell mediated immunity in mice. *Vaccine* **9**:863-4.
 143. Power UF, Plotnicky-Gilquin H, Huss T, Robert A, Trudel M, Stahl S, Uhlen M, Nguyen TN, Binz H. 1997. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. *Virology* **230**:155-66.
 144. Li X, Sambhara S, Li CX, Ewasysshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. 1998. Protection against respiratory syncytial virus infection by DNA immunization. *J Exp Med* **188**:681-8.
 145. Park EK, Soh BY, Jang YS, Park JH, Chung GH. 2001. Immune induction and modulation in mice following immunization with DNA encoding F protein of respiratory syncytial virus. *Mol Cells* **12**:50-6.
 146. Andersson C, Liljestrom P, Stahl S, Power UF. 2000. Protection against respiratory syncytial virus (RSV) elicited in mice by plasmid DNA immunisation encoding a secreted RSV G protein-derived antigen. *FEMS Immunol Med Microbiol* **29**:247-53.
 147. Mohapatra SS. 2003. Mucosal gene expression vaccine: a novel vaccine strategy for respiratory syncytial virus. *Pediatr Infect Dis J* **22**:S100-S104.
 148. Karron RA, Wright PF, Crowe Jr. JE, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR. 1997. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial vaccines in chimpanzees and in human adults, infants, and children. *J Infect Dis* **176**:1428-36.
 149. Wright PF, Karron RA, Belshe RB, Thompson J, Crowe Jr. JE, Boyce TG, Halburnt LL, Reed GW, Whitehead SS, Anderson EL, Wittek AE, Casey R, Eichelberger M, Thumar B, Randolph VB, Udem SA, Chanock RM, Murphy BR. 2000. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. *J Infect Dis* **182**:1331-42.
 150. Jin H, Cheng X, Traina-Dorge VL, Park HJ, Zhou H, Soike K, Kemble G. 2003. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. *Vaccine* **21**:3647-52.
 151. Whitehead SS, Hill MG, Firestone CY, St Claire M, Elkins WR, Murphy BR, Collins PL. 1999. Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. *J Virol* **73**:9773-80.
 152. Schmidt AC, McAuliffe JM, Murphy BR, Collins PL. 2001. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory

- syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. *J Virol* **75**:4594-603.
153. Buchholz UJ, Granzow H, Schuldt K, Whitehead SS, Murphy BR, Collins PL. 2000. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine. *J Virol* **74**:1187-99.
 154. Bossert B, Conzelmann KK. 2002. Respiratory syncytial virus (RSV) nonstructural (NS) proteins as host range determinants: a chimeric bovine RSV with NS genes from human RSV is attenuated in interferon-competent bovine cells. *J Virol* **76**:4287-93.
 155. Crowe Jr. JE, Collins PL, London WT, Chanock RM, Murphy BR. 1993. A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. *Vaccine* **11**:1395-404.
 156. Wyatt LS, Whitehead SS, Venanzi KA, Murphy BR, Moss B. 2000. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. *Vaccine* **18**:392-7.
 157. Corvaia N, Tournier P, Nguyen TN, Haeuw JF, Power UF, Binz H, Andreoni C. 1997. Challenge of BALB/c mice with respiratory syncytial virus does not enhance the Th2 pathway induced after immunization with a recombinant G fusion protein, BBG2NA, in aluminum hydroxide. *J Infect Dis* **176**:560-9.
 158. Plotnicky-Gilquin H, Huss T, Aubry JP, Haeuw JF, Beck A, Bonnefoy JY, Nguyen TN, Power UF. 1999. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. *Virology* **258**:128-40.
 159. Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy JY, Nguyen TN. 2001. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. *J Virol* **75**:12421-30.
 160. Plotnicky H, Siegrist CA, Aubry JP, Bonnefoy JY, Corvaia N, Nguyen TN, Power UF. 2003. Enhanced pulmonary immunopathology following neonatal priming with formalin-inactivated respiratory syncytial virus but not with the BBG2NA vaccine candidate. *Vaccine* **21**:2651-60.
 161. Siegrist CA, Plotnicky-Gilquin H, Cordova M, Berney M, Bonnefoy JY, Nguyen TN, Lambert PH, Power UF. 1999. Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies. *J Infect Dis* **179**:1326-33.
 162. Stickl H, Hochstein-Mintzel V, Mayr A, Huber HC, Schäfer H, Holzner A. 1974. MVA-Stufenimpfung gegen Pocken. Klinische Erprobung des attenuierten Pocken-Lebenimpfstoffes, Stamm MVA. *Dtsch Med Wschr* **99**:2386-92.
 163. Sutter G, Moss B. 1992. Nonreplicating vaccinia vector efficiently expresses recombinant genes. *Proc Natl Acad Sci USA* **89**:10847-51.
 164. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. 1994. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. *Vaccine* **12**:1032-40.
 165. Hirsch VM, Fuerst TR, Sutter G, Carroll MW, Yang LC, Goldstein S, Piatak M, Elkins WR, Alvord WG, Montefiori DC, Moss B, Lifson JD. 1996. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. *J Virol* **70**:3741-52.

166. Schneider J, Gilbert SC, Blanchard TJ, Hanke T, Robson KJ, Hannan CM, Becker M, Sinden R, Smith GL, Hill AVS. 1998. Enhanced immunogenicity for CD8⁺ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. *Nat Med* **4**:397-402.
167. Stittelaar KJ, Kuiken T, De Swart RL, Van Amerongen G, Vos HW, Niesters HGM, van Schalkwijk P, van der Kwast T, Wyatt LS, Moss B, Osterhaus ADME. 2001. Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques. *Vaccine* **19**:3700-9.
168. Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJM. 1998. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. *J Immunol* **161**:6215-22.
169. Dreizin RS, Vyshnevetskaia LO, Bagdamian EE, Iankevich OD, Tarasova LB. 1971. Experimental RS virus infection of cotton rats. A viral and immunofluorescent study. *Vopr Virusol* **16**:670-6.
170. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. *Am J Pathol* **93**:771-91.
171. Prince GA, Horswood RL, Berndt J, Suffin SC, Chanock RM. 1979. Respiratory syncytial virus infection in inbred mice. *Infect Immun* **26**:764-6.
172. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. *J Gen Virol* **82**:2881-8.
173. Homa FL, Brideau RJ, Lehman DJ, Thomsen DR, Olmsted RA, Wathen MW. 1993. Development of a novel subunit vaccine that protects cotton rats against both human respiratory syncytial virus and human parainfluenza virus type 3. *J Gen Virol* **74**:1995-9.
174. Blanco JCG, Richardson JY, Darnell MER, Rowzee A, Pletneva L, Porter DD, Prince GA. 2002. Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. *J Infect Dis* **185**:1780-5.
175. Larsen LE. 2000. Bovine respiratory syncytial virus (BRSV): a review. *Acta Vet Scand* **41**:1-24.
176. Schreiber P, Matheise JP, Dessy F, Heimann M, Letesson JJ, Coppe P, Collard A. 2000. High mortality rate associated with bovine respiratory syncytial virus (BRSV) infection in Belgian White Blue calves previously vaccinated with an inactivated BRSV vaccine. *J Vet Med B* **47**:535-50.
177. Gershwin LJ, Schelegle ES, Gunther RA, Anderson ML, Woolums AR, Larochelle DR, Boyle GA, Friebertshauser KE, Singer RS. 1998. A bovine model of vaccine enhanced respiratory syncytial virus pathophysiology. *Vaccine* **16**:1225-36.
178. Antonis AFG, Schrijver RS, Daus FJ, Steverink PJGM, Stockhofe N, Hensen EJ, Langedijk JPM, Van der Most RG. 2003. Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis. *J Virol* **77**:12067-73.
179. Belshe RB, Richardson LS, London WT, Sly DL, Lorfeld JH, Camargo E, Prevar DA, Chanock RM. 1977. Experimental respiratory syncytial infection of four species of primates. *J Med Virol* **1**:157-62.
180. Kakuk TJ, Soike K, Brideau RJ, Zaya RM, Cole SL, Zhang J-Y, Roberts ED, Wells PA, Wathen MW. 1993. A human respiratory syncytial virus (RSV) primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. *J Infect Dis* **167**:553-61.

181. Prince GA, Suffin SC, Prevar DA, Camargo E, Sly DL, London WT, Chanock RM. 1979. Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-type virus and two temperature-sensitive mutants. *Infect Immun* **26**:1009-13.
182. Koff WC, Caplan FR, Case S, Halstead SB. 1983. Cell-mediated immune response to respiratory syncytial virus infection in owl monkeys. *Clin Exp Immunol* **53**:272-80.
183. McArthur-Vaughan K, Gershwin LJ. 2002. A rhesus monkey model of respiratory syncytial virus infection. *J Med Primatol* **31**:61-73.
184. Babu PG, Selvan A, Christuraj S, David J, John TJ, Simoes EA. 1998. A primate model of respiratory syncytial virus infection. *Indian J Exp Biol* **36**:758-62.
185. Simoes EAF, Hayward AR, Ponnuraj EM, Straumanis JP, Stenmark KR, Wilson HL, Babu PG. 1999. Respiratory syncytial virus infects the Bonnet monkey, *Macaca radiata*. *Ped Dev Pathol* **2**:316-26.
186. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. *Am J Epidemiol* **89**:435-48.
187. Chin J, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. *Am J Epidemiol* **89**:449-63.
188. Prince GA, Jenson AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, Chanock RM. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. *J Virol* **57**:721-8.
189. Connors M, Kulkarni AB, Firestone C-Y, Holmes KL, Morse III HC, Sotnikov AV, Murphy BR. 1992. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4⁺ T cells. *J Virol* **66**:7444-51.
190. Graham BS. 1995. Pathogenesis of respiratory syncytial virus vaccine-augmented pathology. *Am J Respir Crit Care Med* **152**:S63-S66.
191. Openshaw PJM, Clarke SL, Record FM. 1992. Pulmonary eosinophilic response to respiratory syncytial virus in mice sensitized to the major surface glycoprotein G. *Int Immunol* **4**:493-500.
192. Alwan WH, Kozłowska WJ, Openshaw PJM. 1994. Distinct types of lung disease caused by functional subsets of antiviral T cells. *J Exp Med* **179**:81-9.
193. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. 1998. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. *J Virol* **72**:2871-80.
194. Wennergren G, Kristjansson S. 2001. Relationship between respiratory syncytial virus bronchiolitis and future obstructive airway diseases. *Eur Respir J* **18**:1044-58.
195. McBride JT. 1999. Pulmonary function changes in children after respiratory syncytial virus infection in infancy. *J Pediatr* **135**:28-32.
196. Peebles Jr. RS, Sheller JR, Collins RD, Jarzecka AK, Mitchell DB, Parker RA, Graham BS. 2001. Respiratory syncytial virus infection does not increase allergen-induced type 2 cytokine production, yet increases airway hyperresponsiveness in mice. *J Med Virol* **63**:178-88.
197. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM, Corry DB. 1998. Requirement for IL-13 independently of IL-4 in experimental asthma. *Science* **282**:2261-3.

198. Van Binnendijk RS, Poelen MCM, De Vries P, Voorma HO, Osterhaus ADME, UytdeHaag FGCM. 1989. Measles virus-specific human T cell clones. Characterization of specificity and function of CD4⁺ helper/cytotoxic and CD8⁺ cytotoxic T cell clones. *J Immunol* **142**:2847-54.
199. Bangham CRM, McMichael AJ. 1986. Specific human cytotoxic T cells recognize B-cell lines persistently infected with respiratory syncytial virus. *Proc Natl Acad Sci USA* **83**:9183-7.
200. Verjans GMGM, Remeijer L, Van Binnendijk RS, Cornelissen JGC, Volker-Dieben HJ, Baarsma SG, Osterhaus ADME. 1998. Identification and characterization of herpes simplex virus-specific CD4⁺ T cells in corneas of herpetic stromal keratitis patients. *J Infect Dis* **177**:484-8.
201. Hall CB, Hall WJ, Speers DM. 1979. Clinical and physiological manifestations of bronchiolitis and pneumonia. Outcome of respiratory syncytial virus. *Am J Dis Child* **133**:798-802.
202. Martin AJ, Gardner PS, McQuillin J. 1978. Epidemiology of respiratory viral infection among paediatric inpatients over a six-year period in north-east England. *Lancet* **2**:1035-8.
203. Weigl JAI, Puppe W, Schmitt HJ. 2001. Incidence of respiratory syncytial virus-positive hospitalizations in Germany. *Eur J Clin Microbiol Infect Dis* **20**:452-9.
204. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JLL. 2001. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. *J Infect Dis* **184**:355-8.
205. Griffin DE. 1995. Immune responses during measles virus infection. *Curr Top Microbiol Immunol* **191**:117-34.
206. Corry DB. 1999. IL-13 in allergy: home at last. *Curr Opin Immunol* **11**:610-4.
207. Openshaw PJM. 2001. Potential mechanisms causing delayed effects of respiratory syncytial virus infection. *Am J Respir Crit Care Med* **163**:S10-S13.
208. O'Sullivan S, Cormican L, Faul JL, Ichinohe S, Johnston SL, Burke CM, Poulter LW. 2001. Activated, Cytotoxic CD8⁺ T Lymphocytes Contribute to the Pathology of Asthma Death. *Am J Respir Crit Care Med* **164**:560-4.
209. Cannon MJ, Openshaw PJM, Askonas BA. 1988. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. *J Exp Med* **168**:1163-8.
210. Alwan WH, Record FM, Openshaw PJM. 1992. CD4⁺ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8⁺ T cells. *Clin Exp Immunol* **88**:527-36.
211. Bangham CRM, Openshaw PJM, Ball LA, King AMQ, Wertz GW, Askonas BA. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoproteins (G), expressed by vaccinia virus recombinants. *J Immunol* **137**:3973-7.
212. Cannon MJ, Bangham CRM. 1989. Recognition of Respiratory Syncytial Virus Fusion Protein by Mouse cytotoxic T Cell Clones and a Human Cytotoxic T Cell Line. *J Gen Virol* **70**:79-87.
213. Cherrie AH, Anderson K, Wertz GW, Openshaw PJM. 1992. Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus. *J Virol* **66**:2102-10.
214. Van Binnendijk RS, Versteeg-van Oosten JPM, Poelen MCM, Brugghe HF, Hoogerhout P, Osterhaus ADME, UytdeHaag FGCM. 1993. Human HLA class I- and

- HLA Class II-restricted cloned cytotoxic T lymphocytes identify a cluster of epitopes on the measles virus fusion protein. *J Virol* **67**:2276-84.
215. Collins PL, Huang YT, Wertz GW. 1984. Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. *Proc Natl Acad Sci USA* **81**:7683-7.
 216. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. *Proc Natl Acad Sci USA* **83**:7462-6.
 217. Wiertz EJ, Gaans-van den Brink JA, Gausepohl H, Prochnicka-Chalufour A, Hoogerhout P, Poolman JT. 1992. Identification of T cell epitopes occurring in a meningococcal class I outer membrane protein using overlapping peptides assembled with simultaneous multiple peptide synthesis. *J Exp Med* **176**:79-88.
 218. Van Binnendijk RS, Poelen MCM, Kuijpers KC, Osterhaus ADME, UytdeHaag FGCM. 1990. The predominance of CD8⁺ T cells after infection with measles virus suggests a role for CD8⁺ class I MHC-restricted cytotoxic T lymphocytes (CTL) in recovery from measles. *J Immunol* **144**:2394-9.
 219. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. 1993. Allergen immunotherapy decreases interleukin 4 production in CD4⁺ T cells from allergic individuals. *J Exp Med* **178**:2123-30.
 220. Evans TG, Fitzgerald T, Gibbons DC, Keefer MC, Soucier H. 1998. Th1/Th2 cytokine responses following HIV-1 immunization in seronegative volunteers. The AIDS Vaccine Evaluation Group. *Clin Exp Immunol* **111**:243-50.
 221. Kallas EG, Gibbons DC, Soucier H, Fitzgerald T, Treanor JJ, Evans TG. 1999. Detection of intracellular antigen-specific cytokines in human T cell populations. *J Infect Dis* **179**:1124-31.
 222. Bangham CRM, Cannon MJ, Karzon DT, Askonas BA. 1985. Cytotoxic T-cell response to respiratory syncytial virus in mice. *J Virol* **56**:55-9.
 223. Chiba Y, Higashidate Y, Suga K, Honjo K, Tsatsumi H, Ogra PL. 1989. Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection. *J Med Virol* **28**:133-9.
 224. Isaacs D, Bangham CRM, McMichael AJ. 1987. Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis. *Lancet* **2**:769-71.
 225. de Waal L, Koopman LP, van Benten IJ, Brandenburg AH, Mulder PGH, De Swart RL, Fokkens WJ, Neijens HJ, Osterhaus ADME. 2003. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. *J Med Virol* **70**:309-18.
 226. Brandenburg AH, de Waal L, Timmerman HH, Hoogerhout P, De Swart RL, Osterhaus ADME. 2000. HLA class-I restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion protein. *J Virol* **74**:10240-4.
 227. Verjans GM, Janssen R, UytdeHaag FG, van Doornik CE, Tommassen J. 1995. Intracellular processing and presentation of T cell epitopes, expressed by recombinant *Escherichia coli* and *Salmonella typhimurium*, to human T cells. *Eur J Immunol* **25**:405-10.
 228. Fields CG, Lloyd DH, MacDonald RL, Otteson KM, Noble RL. 1991. HBTU activation for automated Fmoc solid phase peptide synthesis. *Peptide Res* **4**:95-101.
 229. Stittelaar KJ, Wyatt LS, De Swart RL, Vos HW, Groen J, Van Amerongen G, Van Binnendijk RS, Rozenblatt S, Moss B, Osterhaus ADME. 2000. Protective immunity in macaques vaccinated with a Modified Vaccinia virus Ankara-based measles vaccine in the presence of passively acquired antibodies. *J Virol* **74**:4236-43.

230. Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, Gahery-Segard H, Guillet JG, Menez A, Georges B, Maillere B. 2002. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. *J Immunol* **169**:6928-34.
231. Moreau P, Cesbron A. 1994. HLA-DP and allogeneic bone marrow transplantation. *Bone Marrow Transplant* **13**:675-81.
232. Austin P, Trowsdale J, Rudd C, Bodmer W, Feldmann M, Lamb J. 1985. Functional expression of HLA-DP genes transfected into mouse fibroblasts. *Nature* **313**:61-4.
233. Celis E, Larson J, Otvos L, Jr., Wunner WH. 1990. Identification of a rabies virus T cell epitope on the basis of its similarity with a hepatitis B surface antigen peptide presented to T cells by the same MHC molecule (HLA-DPw4). *J Immunol* **145**:305-10.
234. Koelle DM, Reymond SN, Chen H, Kwok WW, McClurkan C, Gyaltsong T, Petersdorf EW, Rotkis W, Talley AR, Harrison DA. 2000. Tegument-specific, virus-reactive CD4 T cells localize to the cornea in herpes simplex virus interstitial keratitis in humans. *J Virol* **74**:10930-8.
235. Baselmans PJ, Pollabauer E, van Reijssen FC, Heystek HC, Hren A, Stumptner P, Tilanus MG, Vooijs WC, Mudde GC. 2000. IgE production after antigen-specific and cognate activation of HLA-DPw4-restricted T-cell clones, by 78% of randomly selected B-cell donors. *Hum Immunol* **61**:789-98.
236. Al Daccak R, Wang FQ, Theophille D, Lethielleux P, Colombani J, Loiseau P. 1991. Gene polymorphism of HLA-DPB1 and DPA1 loci in caucasoid population: frequencies and DPB1-DPA1 associations. *Hum Immunol* **31**:277-85.
237. Ponnuraj EM, Hayward AR, Raj A, Wilson H, Simoes EAF. 2001. Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (*Macaca radiata*) pre-immunized with a formalin-inactivated RSV vaccine. *J Gen Virol* **82**:2663-74.
238. Fulginiti VA, Eller JJ, Downte AW, Kempe CH. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated virus vaccines. *JAMA* **202**:1075-80.
239. Dagouassat N, Robillard V, Haeuw JF, Plotnicky-Gilquin H, Power UF, Corvaia N, Nguyen T, Bonnefoy JY, Beck A. 2001. A novel bipolar mode of attachment to aluminium-containing adjuvants by BBG2Na, a recombinant subunit hRSV vaccine. *Vaccine* **19**:4143-52.
240. Reed LJ, Muench H. 1938. A simple method of estimating fifty percent endpoints. *Am J Hygiene* **27**:493-7.
241. Trudel, M., Power, U. F., Stahl, S., Bonnefoy, J. Y., and Nguyen, T. N. 1998. Immunogenicity and protective efficacy of an RSV subunit vaccine candidate BBG2Na in African green monkeys. Abstract, ICAAC San Diego.
242. de Waal L, Power UF, Yuksel S, Van Amerongen G, Nguyen TN, Niesters HGM, De Swart RL, Osterhaus ADME. Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. *Vaccine* (*in press*)
243. Zhu Y-D, Rota P, Wyatt LS, Tamin A, Rozenblatt S, Lerche N, Moss B, Bellini W, McChesney M. 2000. Evaluation of recombinant vaccinia virus - measles vaccines in infant rhesus macaques with preexisting measles antibody. *Virology* **276**:202-13.
244. Nilsson C, Sutter G, Walther-Jallow L, Ten Haaf P, Akerblom L, Heeney J, Erfle V, Bottiger P, Biberfeld G, Thorstensson R. 2002. Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. *J Gen Virol* **83**:807-18.

245. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. *J Virol* **77**:799-803.
246. Peebles Jr. RS, Hashimoto K, Graham BS. 2003. The complex relationship between respiratory syncytial virus and allergy in lung disease. *Viral Immunol* **16**:25-34.
247. Koopman LP. Risk factors for the development of atopic disease in infancy and early childhood. PhD thesis. Rotterdam: Optima Grafische Communicatie, 2002.
248. van Benten IJ. Viral respiratory infections and maturation of nasal immune responses: the VIGALL study. PhD thesis. Rotterdam: Optima Grafische Communicatie, 2004.
249. Appay V, Rowland-Jones SL. 2002. The assessment of antigen-specific CD8⁺ T cells through the combination of MHC class I tetramer and intracellular staining. *J Immunol Methods* **268**:9-19.
250. Xu XN, Screaton GR. 2002. MHC/peptide tetramer-based studies of T cell function. *J Immunol Methods* **268**:21-8.
251. Novak EJ, Liu AW, Nepom GT, Kwok WW. 1999. MHC class II tetramers identify peptide-specific human CD4⁺ T cells proliferating in response to influenza A antigen. *J Clin Invest* **104**:R63-R67.
252. Novak EJ, Masewicz SA, Liu AW, Lernmark A, Kwok WW, Nepom GT. 2001. Activated human epitope-specific T cells identified by class II tetramers reside within a CD4^{high}, proliferating subset. *Int Immunol* **13**:799-806.
253. Cameron TO, Norris PJ, Patel A, Moulon C, Rosenberg ES, Mellins ED, Wedderburn LR, Stern LJ. 2002. Labeling antigen-specific CD4⁺ T cells with class II MHC oligomers. *J Immunol Methods* **268**:51-69.
254. Kwok WW, Ptacek NA, Liu AW, Buckner JH. 2002. Use of class II tetramers for identification of CD4⁺ T cells. *J Immunol Methods* **268**:71-81.
255. Boon ACM, de Mutsert G, Graus YMF, Fouchier RAM, Sintnicolaas K, Osterhaus ADME, Rimmelzwaan GF. 2002. Sequence variation in a newly identified HLA-B35-restricted epitope in the influenza A virus nucleoprotein associated with escape from cytotoxic T lymphocytes. *J Virol* **76**:2567-72.
256. de Waal L, Yüksel S, Brandenburg AH, Langedijk JPM, Sintnicolaas K, Verjans GMGM, Osterhaus ADME, de Swart RL. Identification of a common HLA-DP4-restricted T cell epitope in the conserved region of the respiratory syncytial virus G protein. *J Virol* (*in press*)
257. de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B, Niesters HGM, Osterhaus ADME, de Swart RL. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. *Vaccine* (*in press*)